Lake Street Maintains Buy on Better Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a 'Buy' rating on Better Therapeutics (NASDAQ:BTTX), but has lowered the price target from $5 to $3.
August 10, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Better Therapeutics' price target has been lowered from $5 to $3 by Lake Street, though the 'Buy' rating is maintained.
The lowering of the price target indicates that the analyst sees less upside potential in the stock, which could lead to a negative sentiment among investors. However, the maintained 'Buy' rating suggests that the analyst still believes the stock is a good investment, which could counteract some of the negative sentiment. The net impact on the stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100